• SMX (Security Matters) Public Limited Company saw a remarkable 779.91% increase in its stock price, driven by the expansion of its "Proof as Currency" platform.
• Abrdn Australia Equity Fund Inc experienced a 194.31% increase in its stock price, following the announcement of a 1-for-3 reverse stock split.
• Scienture Holdings, Inc. (SCNX) saw a 130.97% rise in its stock price, with the commencement of commercial sales for Arbli™ (losartan potassium) Oral Suspension.

In a dynamic trading day, several companies have emerged as top gainers, showcasing significant price movements. SMX (Security Matters) Public Limited Company, Abrdn Australia Equity Fund Inc, Scienture Holdings, Inc., Franklin Templeton ETF Trust, and Ventyx Biosciences, Inc. have made notable strides. Each company has shown unique growth, driven by strategic initiatives and market developments.

SMX (Security Matters) Public Limited Company saw a remarkable 779.91% increase in its stock price, reaching $7.62. This surge is supported by the company's expansion of its "Proof as Currency" platform, which enhances its value proposition. The lean share structure further accelerates SMX's growth, attracting heightened investor interest with a trading volume of 310,803.

Abrdn Australia Equity Fund Inc experienced a 194.31% increase in its stock price, climbing to $13.45. The fund's announcement of a 1-for-3 reverse stock split, set for October 23, 2025, reflects strategic financial restructuring. This move, approved by the Fund's Board of Directors, aims to boost investor confidence, despite a trading volume slightly below average at 13,154.

Scienture Holdings, Inc. (SCNX) saw a 130.97% rise in its stock price, reaching $1.32. The company's commencement of commercial sales for Arbli™ (losartan potassium) Oral Suspension marks a significant milestone. With the U.S. losartan market valued at $256 million annually, this FDA-approved product presents a substantial opportunity, driving a massive trading volume of 579,369,821.

Ventyx Biosciences, Inc. showcased a 90.28% increase in its stock price, reaching $7.34. The company's positive topline results from its Phase 2 study of VTX3232 in participants with obesity and cardiovascular risk factors have fueled market optimism. The study's significant reductions in cardiovascular risk factors highlight Ventyx's potential market impact, reflected in a trading volume of 103,871,432.

These movements reflect a dynamic trading day, with significant investor interest and market activity surrounding these companies. Each company's unique position, whether in biotechnology, asset management, or healthcare information services, contributes to the diverse landscape of opportunities for investors.